Form 4: Macrogenics Executive Sells Shares Under 10b5-1 Trading Plan

Jeffrey Stuart Peters, Senior VP and General Counsel of Macrogenics, Inc., executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 6, 2024, Jeffrey Stuart Peters, Senior VP and General Counsel of Macrogenics Inc., engaged in transactions involving the company's common stock.
• Peters exercised employee stock options to acquire 10,875 shares at $11.50 and 8,750 shares at $10.15.
• Simultaneously, Peters sold 19,625 shares of common stock at $21.50.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2022.
• Following these transactions, Peters directly owns 8,895 shares of Macrogenics common stock and holds options to purchase 39,375 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports transactions under a pre-existing trading plan, with no indication of positive or negative implications for the company.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. The use of 10b5-1 plans allows insiders to sell shares without being accused of acting on non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates